GlassScriptPhysician profile
Patricia King
NPI 1114956638
$18,019.99
in general payments reported to CMS, 2019-2025
25 companies · $5,086 in 2025
The $5,086 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.33 · 2020: $226 · 2021: $929 · 2022: $1,142 · 2023: $1,538 · 2024: $9,028 · 2025: $5,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,944 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,700.00 |
| Food and Beverage | $3,943.56 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,995.95 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $887.66 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $630.64 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $500.59 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $466.49 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $339.70 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $336.90 | 2020-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $301.77 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $195.09 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $179.32 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $174.87 | 2019-2025 | Ingrezza |
| Tris Pharma INC | $146.87 | 2021-2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $119.48 | 2020-2022 | |
| Almatica Pharma LLC | $108.72 | 2021-2024 | Gralise, Loreev Xr |
| Axsome Therapeutics, INC. | $101.47 | 2023-2025 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $84.63 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $83.72 | 2022-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $75.89 | 2020 | |
| Eisai INC. | $60.00 | 2020-2022 | |
| Corium, LLC | $58.16 | 2022-2024 | Azstarys |
| Noven Therapeutics, LLC | $57.07 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $53.85 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $31.14 | 2020-2021 | |
| Neos Therapeutics, LP | $17.44 | 2022 | |
| Merck Sharp & Dohme LLC | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.